Compare BridgeBio Pharma Inc (BBIO) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Alliant Energy Corporation — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while Alliant Energy Corporation trades at $76.6 (market cap $19.71B). The key difference: Alliant Energy Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays a 2.73% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LNT | |
|---|---|---|
Market Cap | $16.46B | $19.71B |
Sector | Health | Utilities |
52-Week High | $90.17 | $78.03 |
52-Week Low | $44.81 | $61.85 |
Enterprise Value | $18.02B | $31.43B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Alliant Energy (LNT) trades at $76.63, up 0.3% today, near the consensus price target of $76.50. The stock shows a bullish technical trend with strong moving average signals. Recent earnings have mostly beaten estimates, with Q1 2026 EPS of $0.82 exceeding expectations. The company's $13.4 billion clean energy investment plan aims to capitalize on data center demand and drive 5-7% annual earnings growth, supported by rising operating cash flow and a solid 18.58% net income margin.
LNT presents a balanced opportunity with steady utility earnings and growth initiatives, but faces risks from high capital expenditure and rising debt levels. Analyst sentiment is positive with a 52% buy rating, though the stock's valuation multiples like a P/E of 24.1 suggest limited near-term upside without significant earnings acceleration. Regulatory approvals and execution on its investment plan are critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
